157 related articles for article (PubMed ID: 29966384)
1. p19-Targeting ILP Protein Blockers of IL-23/Th-17 Pro-Inflammatory Axis Displayed on Engineered Bacteria of Food Origin.
Škrlec K; Zadravec P; Hlavničková M; Kuchař M; Vaňková L; Petroková H; Křížová L; Černý J; Berlec A; Malý P
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29966384
[TBL] [Abstract][Full Text] [Related]
2. Engineered
Plavec TV; Kuchař M; Benko A; Lišková V; Černý J; Berlec A; Malý P
Microorganisms; 2019 May; 7(5):. PubMed ID: 31137908
[No Abstract] [Full Text] [Related]
3. p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells.
Křížová L; Kuchař M; Petroková H; Osička R; Hlavničková M; Pelák O; Černý J; Kalina T; Malý P
Autoimmunity; 2017 Mar; 50(2):102-113. PubMed ID: 28100093
[TBL] [Abstract][Full Text] [Related]
4. Secretion and surface display of binders of IL-23/IL-17 cytokines and their receptors in Lactococcus lactis as a therapeutic approach against inflammation.
Plavec TV; Klemenčič K; Kuchař M; Malý P; Berlec A
Eur J Pharm Sci; 2023 Nov; 190():106568. PubMed ID: 37619953
[TBL] [Abstract][Full Text] [Related]
5. Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody.
Zahirović A; Berlec A
Microb Cell Fact; 2022 Jul; 21(1):143. PubMed ID: 35842694
[TBL] [Abstract][Full Text] [Related]
6. Improvement of LysM-mediated surface display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus Species.
Zadravec P; Štrukelj B; Berlec A
Appl Environ Microbiol; 2015 Mar; 81(6):2098-106. PubMed ID: 25576617
[TBL] [Abstract][Full Text] [Related]
7. Development of Recombinant Lactococcus lactis Displaying Albumin-Binding Domain Variants against Shiga Toxin 1 B Subunit.
Zadravec P; Marečková L; Petroková H; Hodnik V; Perišić Nanut M; Anderluh G; Štrukelj B; Malý P; Berlec A
PLoS One; 2016; 11(9):e0162625. PubMed ID: 27606705
[TBL] [Abstract][Full Text] [Related]
8. Lactic Acid Bacteria with Concomitant IL-17, IL-23 and TNFα- Binding Ability for the Treatment of Inflammatory Bowel Disease.
Kosler S; Strukelj B; Berlec A
Curr Pharm Biotechnol; 2017; 18(4):318-326. PubMed ID: 28190384
[TBL] [Abstract][Full Text] [Related]
9. Receptor binding domain of Escherichia coli F18 fimbrial adhesin FedF can be both efficiently secreted and surface displayed in a functional form in Lactococcus lactis.
Lindholm A; Smeds A; Palva A
Appl Environ Microbiol; 2004 Apr; 70(4):2061-71. PubMed ID: 15066797
[TBL] [Abstract][Full Text] [Related]
10. ABD-Derived Protein Blockers of Human IL-17 Receptor A as Non-IgG Alternatives for Modulation of IL-17-Dependent Pro-Inflammatory Axis.
Hlavničková M; Kuchař M; Osička R; Vaňková L; Petroková H; Malý M; Černý J; Arenberger P; Malý P
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304852
[TBL] [Abstract][Full Text] [Related]
11. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa.
Simčič S; Berlec A; Stopinšek S; Štrukelj B; Orel R
World J Microbiol Biotechnol; 2019 Feb; 35(3):45. PubMed ID: 30810891
[TBL] [Abstract][Full Text] [Related]
12. Cell surface display system for Lactococcus lactis: a novel development for oral vaccine.
Raha AR; Varma NR; Yusoff K; Ross E; Foo HL
Appl Microbiol Biotechnol; 2005 Jul; 68(1):75-81. PubMed ID: 15635459
[TBL] [Abstract][Full Text] [Related]
13. Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells.
Kuchař M; Vaňková L; Petroková H; Cerný J; Osička R; Pelák O; Sípová H; Schneider B; Homola J; Sebo P; Kalina T; Malý P
Proteins; 2014 Jun; 82(6):975-89. PubMed ID: 24549990
[TBL] [Abstract][Full Text] [Related]
14. Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities.
Škrlec K; Ručman R; Jarc E; Sikirić P; Švajger U; Petan T; Perišić Nanut M; Štrukelj B; Berlec A
Appl Microbiol Biotechnol; 2018 Dec; 102(23):10103-10117. PubMed ID: 30191288
[TBL] [Abstract][Full Text] [Related]
15. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.
Martín R; Chain F; Miquel S; Natividad JM; Sokol H; Verdu EF; Langella P; Bermúdez-Humarán LG
Hum Vaccin Immunother; 2014; 10(6):1611-21. PubMed ID: 24732667
[TBL] [Abstract][Full Text] [Related]
16. Display of heterologous proteins on the surface of Lactococcus lactis using the H and W domain of PrtB from Lactobacillus delburueckii subsp. bulgaricus as an anchoring matrix.
Kim TW; Igimi S; Kajikawa A; Kim HY
J Appl Microbiol; 2008 Jun; 104(6):1636-43. PubMed ID: 18298534
[TBL] [Abstract][Full Text] [Related]
17. Immobilization of nisin producer Lactococcus lactis strains to chitin with surface-displayed chitin-binding domain.
Simşek Ö; Sabanoğlu S; Çon AH; Karasu N; Akçelik M; Saris PE
Appl Microbiol Biotechnol; 2013 May; 97(10):4577-87. PubMed ID: 23354445
[TBL] [Abstract][Full Text] [Related]
18. Immobilization of Lactococcus lactis to cellulosic material by cellulose-binding domain of Cellvibrio japonicus.
Kylä-Nikkilä K; Alakuijala U; Saris PE
J Appl Microbiol; 2010 Oct; 109(4):1274-83. PubMed ID: 20497279
[TBL] [Abstract][Full Text] [Related]
19. Trimming of two major type 1 diabetes driving antigens, GAD65 and IA-2, allows for successful expression in Lactococcus lactis.
Robert S; Van Huynegem K; Gysemans C; Mathieu C; Rottiers P; Steidler L
Benef Microbes; 2015; 6(4):591-601. PubMed ID: 25576592
[TBL] [Abstract][Full Text] [Related]
20. Expression of biologically active murine interleukin-18 in Lactococcus lactis.
Feizollahzadeh S; Khanahmad H; Rahimmanesh I; Ganjalikhani-Hakemi M; Andalib A; Sanei MH; Rezaei A
FEMS Microbiol Lett; 2016 Nov; 363(21):. PubMed ID: 27864297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
